Drug Profile


Alternative Names: ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; Cresemba; Isavuconazonium sulfate; Isavuconazonium sulphate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Astellas Pharma; Basilea Pharmaceutica
  • Class Antifungals; Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis; Aspergillosis; Candidaemia; Zygomycosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Aspergillosis; Zygomycosis
  • Phase III Candidiasis
  • Discontinued Mycoses

Most Recent Events

  • 04 May 2017 The Memorial Sloan Kettering Cancer Center in collaboration with Astellas Pharma initiates a phase II trial for Fungal infections in USA (PO) (IV) (NCT03149055)
  • 15 Nov 2016 Updated efficacy data from the phase III VITAL trial for Zygomycosis released by Basilea Pharmaceutica
  • 20 Sep 2016 Isavuconazonium licensed to Unimedic Pharma in Sweden, Denmark, Norway and Finland for import and commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top